Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc.

Product Sales

Product Sales %Chg

Product Sales Common Size

Royalty, Contract and Other Revenues

Royalty, Contract and Other Revenues %Chg

Royalty, Contract and Other Revenues Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Goods Sold

Cost of Goods Sold %Chg

Cost of Goods Sold Common Size

Research and Development Expenses

Research and Development Expenses %Chg

Research and Development Expenses Common Size

Acquired in-Process Research and Development Expenses

Acquired in-Process Research and Development Expenses %Chg

Acquired in-Process Research and Development Expenses Common Size

In-Process Research and Development Impairments

In-Process Research and Development Impairments %Chg

In-Process Research and Development Impairments Common Size

Selling, General and Administrative Expenses

Selling, General and Administrative Expenses %Chg

Selling, General and Administrative Expenses Common Size

Total Costs and Expenses

Total Costs and Expenses %Chg

Total Costs and Expenses Common Size

Operating Income

Operating Income %Chg

Operating Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Other Income, Net

Other Income, Net %Chg

Other Income, Net Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Income Before Income Taxes

Income Before Income Taxes %Chg

Income Before Income Taxes Common Size

Income Tax Expense

Income Tax Expense %Chg

Income Tax Expense Common Size

Net Income

Net Income %Chg

Net Income Common Size

Net Income Attributable to Noncontrolling Interest

Net Income Attributable to Noncontrolling Interest %Chg

Net Income Attributable to Noncontrolling Interest Common Size

Net Income Attributable to Gilead

Net Income Attributable to Gilead %Chg

Net Income Attributable to Gilead Common Size

Basic Earnings per Share Attributable to Gilead

Basic Earnings per Share Attributable to Gilead %Chg

Basic Earnings per Share Attributable to Gilead Common Size

Diluted Earnings per Share Attributable to Gilead

Diluted Earnings per Share Attributable to Gilead %Chg

Diluted Earnings per Share Attributable to Gilead Common Size

Shares Used in Basic Earnings per Share Attributable to Gilead Calculation

Shares Used in Basic Earnings per Share Attributable to Gilead Calculation %Chg

Shares Used in Basic Earnings per Share Attributable to Gilead Calculation Common Size

Shares Used in Diluted Earnings per Share Attributable to Gilead Calculation

Shares Used in Diluted Earnings per Share Attributable to Gilead Calculation %Chg

Shares Used in Diluted Earnings per Share Attributable to Gilead Calculation Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Minority Interests and Other

Net Income Attributable to Minority Interests and Other %Chg

Net Income Attributable to Minority Interests and Other Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	7,769	7,082	6,667	7,569	7,545	6,954
Total Revenues %Chg	3%	1.8%	-0.3%	6.4%	7%	5.4%
Product Sales
Royalty, Contract and Other Revenues
Cost of Sales	1,569	1,501	1,540	1,581	1,574	1,544
Cost of Goods Sold
Gross Profit	6,200	5,581	5,127	5,988	5,971	5,410
Gross Profit Margin	79.8%	78.8%	76.9%	79.1%	79.1%	77.8%
Selling, General & Administrative Expenses	1,357	1,365	1,258	1,907	1,433	1,377
Selling, General and Administrative Expenses
Research & Development Expenses	1,516	1,742	1,632	1,630	3,650	1,389
Research and Development Expenses
Acquired in-Process Research and Development Expenses
In-Process Research and Development Impairments
Operating Profit	3,327	2,474	2,237	2,452	888	2,644
Operating Income
Operating Margin	42.8%	34.9%	33.6%	32.4%	11.8%	38%
Interest Expense	-256	-254	-260	-249	-238	-237
Interest Expense
Non-Operating Income	569	208	-328	-35	306	-355
Other Income, Net
Other Expense, Net
Total Non-Operating Income	313	-46	-588	-284	68	-592
Income Before Provision for Income Taxes	3,641	2,429	1,649	2,167	956	2,053
Income Before Income Taxes
Provision for Income Taxes	589	468	334	385	-297	438
Income Tax Expense
Consolidated Net Income	3,052	1,960	1,315	1,783	1,253	1,614
Net Income
Net Income Attributable to Minority Interests and Other	—	—	—	—	—	—
Net Income Attributable to Noncontrolling Interest
Net Income Attributable to Common Shareholders	3,052	1,960	1,315	1,783	1,253	1,614
Net Income Attributable to Gilead
Basic EPS	2.5	1.6	1.1	1.4	1	1.3
Diluted EPS	2.4	1.6	1	1.4	1	1.3
Basic Weighted Average Shares Outstanding	1,243	1,245	1,246	1,248	1,247	1,247
Total Shares Outstanding	1,242	1,242	1,245	1,246	1,246	1,246
Diluted Weighted Average Shares Outstanding	1,254	1,255	1,259	1,259	1,254	1,251
EBITDA	4,013	3,165	2,933	3,145	1,578	3,338
Effective Tax Rate	16.2%	19.3%	20.3%	17.8%	-31.1%	21.3%